Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine.
Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.
Tatsuo Kanda received a medical degree in 1991 at Niigata University School of Medicine, Japan, and his PhD in 1999 at Chiba University Graduate School of Medicine, Japan. He had post-doctor training for 3 years under Prof. Ratna Ray and Prof. Ranjit Ray at Saint Louis University, St. Louis, MO, USA. In Dec. 2008, Tatsuo Kanda became a Tenure-track Associate Professor at Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Japan. In Feb. 2013, Tatsuo Kanda was nominated a permanent Associate Professor at Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Japan. In 2017, Tatsuo Kanda became an Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine. For ~25 years, he has focused his scientific interests on the topics related to liver diseases including acute liver failure, viral hepatitis and autoimmune liver diseases, and worked with Prof. Osamu Yokosuka. Tatsuo Kanda is also an expert for hepatitis A virus (HAV), HBV and HCV, and translation and replication of these viruses, and hepatocarcinogenesis. With his expertise in antiviral therapies and hepatitis virus research, Tatsuo Kanda also sees a lot of patients in clinical daily practice. Tatsuo Kanda has published more than 200 articles in peer-reviewed Journal.
New Developments in Brain Injury
Submission Deadline: June 20, 2019 (Open) Submit Now
Lynne Ann Barker, PhD Reader in Cognitive Neuroscience
Department of Psychology, Sociology and Politics, Sheffield Hallam University, Sheffield, United Kingdom
E-Mail: [email protected]
Research Interests: Neuropsychology; Cognitive Neuroscience; Brain Trauma; Cognitive assessment; Biomarkers of Neuropathology, Novel Interventions and Therapeutics
Leanne Greene, PhD
1. Researcher, Department of Psychology, Sociology and Politics, Sheffield Hallam University, Sheffield, United Kingdom.
2. Assistant Psychologist, Neurorehabiitation Hub, Rotherham Doncaster & South Humber NHS Trust, Doncaster, UK.
E-Mail: [email protected]
Research Interests: My current PhD research has investigated eye tracking and eye scan paths underpinning social cognition, particularly facial affect recognition, in traumatic brain injury (TBI) and control cohorts. This research builds upon existing evidence concerning social
About This Topic
Estimates of incidence of brain injury across the globe vary considerably, but it is clear that brain injury remains a major cause of death and disability, particularly in youth. Advances in critical care mean that most have normal life expectancy but quality of life is frequently, sometimes devastatingly, compromised. There is an urgent need for new approaches, interventions, therapies, treatments and diagnostic tools that better assess real world capacity and draw on new technologies and advances in science. One particular topic of interest is inconsistency around severity diagnosis (e.g. when to start measuring PTA and GCS, particularly if someone is in a coma or the injury is mild in nature,) and the impact this has on brain injury statistics and rehabilitation. It is a critical priority to develop new ways of standardizing this process. In this special edition we invite submissions that specifically embrace this new spirit of innovation in brain injury assessment, treatment and research. Our aim is to showcase new, inventive and original approaches to longstanding issues in brain injury research and neurorehabilitation.
Manuscripts should be submitted online at http://www.lidsen.com/account-login by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. Guidelines for authors and other relevant information for submission of manuscripts are available on the Instructions for Authors page. OBM Neurobiology is an international peer-reviewed Open Access monthly journal published by LIDSEN. Please visit the Instructions for Authors page before submitting a manuscript.
Title: Role of Hyperglycemia in Preterm Brain Injury
Authors: Katherine Satrom, Tate Gisslen, Raghavendra Rao
Affiliations: Division of Neonatology, University of Minnesota, Minneapolis, MN 55455 (USA)
Title: Role of Erythropoietin in Brain Injury
Authors: Stephana Carelli , Michele Samaja
Affiliation: Department of Health Science, University of Milan, Italy
Abstract: Erythropoietin (EPO), widely known as an erythropoietic hormone, is recognized as a protective messenger in several biological systems, including the cerebrovascular. A downstream protein whose synthesis is triggered by hypoxia-related stresses, EPO exerts its anti-apoptotic and anti-inflammatory effects through its receptor and the activation of the STAT3 pathways, as demonstrated especially in traumatic spinal cord injury. However, it appears that EPO may be related to non-hypoxia-related pathways, such as in Parkinson’s disease, and that hyperoxia, a condition opposite to hypoxia, may be as deleterious as hypoxia in generating brain injury. We will review these mechanisms, evaluating also the potential use of EPO mimics as potential therapeutic targets.